Cyclerion (CYCN) CFO Rhonda Chicko Exercises 25,000 Options

What Happened

• Rhonda M. Chicko, Chief Financial Officer of Cyclerion Therapeutics (CYCN), exercised stock options to acquire 25,000 shares on August 14, 2026 at an exercise price of $2.35 per share, for a cash payment of $58,875. The Form 4 also reports a separate line showing a disposition of 25,000 derivative securities at $0.00; the filing’s footnote explains the option grant and full exercise.
• This is a purchase (exercise of options) rather than an open‑market sale. The reporting indicates Chicko paid cash for the exercise (not a cashless exercise).

Key Details

• Transaction date: 2026-08-14; Form 4 filed: 2026-08-18 (filed within the required reporting window).
• Shares acquired: 25,000 at $2.35 each = $58,875 cash paid.
• Filing also lists 25,000 derivative securities disposed at $0.00 (see footnote for context).
• Footnote summary: Option granted Aug 7, 2025 for up to 25,000 shares (initial partial vesting then monthly vesting through Feb 28, 2028). On July 17, 2026 the board accelerated full vesting; the option was exercised in full on Aug 14, 2026 with cash payment.
• Shares owned after the transaction: not specified in the excerpt of the filing provided.

Context

• For retail investors: exercises mean the insider converted an option into stock by paying the exercise price; it does not necessarily indicate a view on the company’s near‑term prospects. This was not reported as a cashless exercise or an immediate sale of the acquired shares in the Form 4 excerpt provided.
• Transaction code M denotes option exercise. There is no indication in this filing that the insider sold the newly acquired shares.